Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 03 June, 2004

XTL Biopharm Ltd

Cubist and XTL Agreement

XTL Biopharmaceuticals Ltd
03 June 2004

Cubist Pharmaceuticals and XTL Biopharmaceuticals Complete License Agreement for
Worldwide Rights to Hepatitis B Product
Currently in Phase 2b Trials, Product Would Address $100 Million Market for
Prevention of Hepatitis B Infection in Liver Transplant Patients

Lexington, MA and Rehovot, Israel, 3 June 2004 - Cubist Pharmaceuticals, Inc.
(Nasdaq: CBST) and XTL Biopharmaceuticals Ltd. (LSE: XTL) (XTLbio) today
announced the completion of a license agreement for the worldwide development
and commercialisation of XTLbio's investigational monoclonal antibody product
currently known as HepeX-BTM. HepeX-B is in a Phase 2b study for the prevention
of re-infection by the Hepatitis B virus (HBV) in liver transplant patients, a
market currently estimated to be about $100 million worldwide.

The companies will continue the ongoing international Phase 2b study and, if
successful, will continue late-stage clinical development of the product
candidate. Cubist will fund the development costs of HepeX-B and will be solely
responsible for registration and commercialisation of the product worldwide.
Under the terms of the agreement, Cubist will pay XTLbio collaboration support
and an up-front payment totalling $3.0 million over the next two years, and may
pay an additional $3.0 million upon the achievement of certain regulatory
milestones. Cubist has also committed to pay XTLbio a tiered royalty on any
sales generated from HepeX-B that ranges from 10-17% of net sales.

'This commercial agreement represents a significant achievement for XTLbio,'
said Dr. Martin Becker, XTLbio's President and Chief Executive Officer.
'Cubist's focus on antiinfectives and their proven ability to get a product
registered and launched in the U.S. through a seasoned, hospital-focused sales
team made the company a very attractive partner to us. We feel this agreement
not only validates our proprietary technology, but also would provide us with a
revenue stream should HepeX-B ultimately be approved. This agreement is also
consistent with our strategy to leverage our technology through the
establishment of licensing or co-development agreements on candidates that have
achieved clinical proof of principle, and enables us to allocate significant
resources to our ongoing hepatitis C development programs.'

Michael W. Bonney, President and Chief Executive Officer of Cubist commented:
'HepeX-B represents an exciting development opportunity for Cubist. Due to its
potential safety and ease of use advantages over existing therapies, we believe
that HepeX-B has the potential to become the new standard of care for the
prevention of HBV re-infection in liver transplant patients. The product also
fits very well with our experience in the antiinfective area and adds an
important, late-stage development candidate to our pipeline. HepeX-B represents
a unique commercial opportunity, as the market is highly concentrated, with a
limited number of transplant centres around the world performing the majority of
procedures. In the U.S., these institutions overlap fully with Cubist's current
sales effort on Cubicin(R) (daptomycin for injection), our flagship antibiotic
product. We look forward to working with XTLbio to bring this innovative and
valuable product to market.'

XTL Biopharmaceuticals Ltd.:
Dr. Martin Becker
President & CEO
Tel: +972 8 930 4440

David Yates / Julia Phillips
Financial Dynamics
Tel: +44 (0) 20 7831 3113

Cubist Pharmaceuticals, Inc.:
Jennifer LaVin
Executive Director, Corporate Communications
Tel: +1 (781) 860-8362
Euro RSCG Life NRP
Emily Poe - Financial Media
Tel: +1 (212) 845-4266

Notes to Editors

About HBV
Hepatitis B is most commonly caused by the Hepatitis B virus, which, according
to Datamonitor, has infected over 2 billion people around the world. Although a
vaccine against HBV was introduced in 1982, globally, 350 million people are
infected chronically with the disease and approximately 1 million people die
each year as a result of complications from HBV infection. Current treatment
regimens for chronic HBV often include use of interferon alpha or an antiviral
drug. Despite these treatment options, chronic HBV can lead to severe liver
damage and patients may require liver transplantation.

HBV-diseased livers are currently estimated to represent 5% of all liver
transplants in the U.S., or between 200 and 300 liver transplants per year. To
prevent re-infection of the new liver with HBV, patients are currently treated
with HBV immunoglobulin (HBIg) combined with an antiviral compound, such as
lamivudine. The global market for HBIg is estimated to be about $100 million,
despite its limitations, which include large injection volumes, flu-like adverse
events and the risk of blood-borne infections.

About HepeX-B
HepeX-B is a combination of two fully human monoclonal antibodies, selected
using XTLbio's pre-clinical TrimeraTM model, that target HBV surface antigens.
It is currently in an international Phase 2b study for the prevention of
infection by HBV in liver transplant patients. In clinical studies, HepeX-B
maintained serum levels similar to or higher than the current first-line
treatment, HBIg, using 1,000 times less drug. Due to its smaller injection
volume, HepeX-B may be formulated as a subcutaneous injectable product. HepeX-B
has already been granted Orphan Drug Status in both the U.S. and the European

About XTLbio
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeXTM product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
XTLbio believes its primary competitive advantage lies in its patented TrimeraTM
technology, which enables the development of fully human monoclonal antibodies
and models of human disease for pre-clinical drug validation. XTLbio currently
has an ongoing Phase 2a clinical program for hepatitis C associated with liver
transplantation (HepeX-CTM) and preclinical programs for chronic hepatitis C.
Established in 1993, XTLbio became a public company in 2000, with shares traded
on the London Stock Exchange under the symbol XTL.

About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development and commercialization of antiinfective products that meet
unmet medical needs. In the U.S., Cubist markets Cubicin(R) (daptomycin for
injection), the first antibiotic in a new class of antiinfectives called
lipopeptides, for the indication of complicated skin and skin structure
infections caused by certain Gram-positive bacteria. CUBICIN is currently the
only once-daily bactericidal antibiotic approved in the U.S. with activity
against both methicillin-susceptible and methicillin-resistant Staphylococcus
aureus (MSSA and MRSA). Cubist's pipeline includes HepeX-BTM, a monoclonal
antibody biologic currently in a Phase 2b study for the prevention of infection
by the Hepatitis B virus (HBV) in liver transplant patients, and research
efforts focused on novel members of the lipopeptide class of molecules. Cubist
is headquartered in Lexington, MA.

Cubist Safe Harbor Statement

Statements contained herein that are not historical fact may be forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and such statements are
subject to a variety of risks and uncertainties. There are a number of important
factors that could cause actual results to differ materially from those
projected or suggested in any forward-looking statements made by Cubist. These
factors include, but are not limited to: (i) the level of acceptance of CUBICIN
by physicians, patients, third-party payors, and the medical community
generally; (ii) Cubist's ability to continue to develop, secure additional
regulatory approvals for, and successfully market, CUBICIN; (iii) Cubist's
ability to manufacture CUBICIN on a commercial scale; (iv) commercialization of
products that are competitive with CUBICIN; (v) Cubist's ability to discover or
in-license drug candidates; (vi) Cubist's ability to successfully develop drug
candidates in its pipeline, including HepeX-B; (vii) Cubist's ability to
successfully commercialize any product or technology developed by Cubist; (viii)
Cubist's ability to establish and maintain successful manufacturing, sales and
marketing, distribution, and development collaborations; (ix) legislative or
regulatory changes adversely affecting Cubist or the biopharmaceutical industry;
(x) Cubist's ability to protect its intellectual property and proprietary
technologies; and (xi) Cubist's ability to finance its operations. Additional
factors that could cause actual results to differ materially from those
projected or suggested in any forward-looking statements are contained in
Cubist's recent filings with the Securities and Exchange Commission, including
those factors discussed under the caption 'Risk Factors' in such filings.

Cubist and Cubicin are registered trademarks of Cubist Pharmaceuticals, Inc.;
HepeX-B and Trimera are trademarks of XTL Biopharmaceuticals Ltd.

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t